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Abstract: Thermosensitive liposomes are a promising tool for external targeting of drugs to solid 
tumors when used in combination with local hyperthermia or high intensity focused ultrasound. 
In vivo results have demonstrated strong evidence that external targeting is superior over passive 
targeting achieved by highly stable long-circulating drug formulations like PEGylated liposomal 
doxorubicin. Up to March 2014, the Web of Science listed 371 original papers in this field, with 45 
in 2013 alone. Several formulations have been developed since 1978, with lysolipid-containing, low 
temperature-sensitive liposomes currently under clinical investigation. This review summarizes the 
historical development and effects of particular phospholipids and surfactants on the biophysical 
properties and in vivo efficacy of thermosensitive liposome formulations. Further, treatment strate-
gies for solid tumors are discussed. Here we focus on temperature-triggered intravascular and inter-
stitial drug release. Drug delivery guided by magnetic resonance imaging further adds the possibility 
of performing online monitoring of a heating focus to calculate locally released drug concentrations 
and to externally control drug release by steering the heating volume and power. The combination 
of external targeting with thermosensitive liposomes and magnetic resonance-guided drug delivery 
will be the unique characteristic of this nanotechnology approach in medicine.
Keywords: thermosensitive liposomes, phosphatidyloligoglycerol, hyperthermia, high intensity 
focused ultrasound, drug delivery, drug targeting
Thermosensitive liposomes and their historical 
development
Liposomes are spherical vesicles formed by a membrane bilayer usually composed by 
phospholipids (Figure 1). The membrane encloses an aqueous core that can be used 
to encapsulate hydrophilic drugs, whereas lipophilic drugs can be incorporated into 
the membrane. Several methods are available for preparation of liposomal formula-
tions, ranging from laboratory scale to Good Manufacturing Practice production for 
clinical batches.1 Loading of drugs can be achieved by active (Figure 2A) or passive 
(Figure 2B) loading methods. Stable encapsulation of a drug inside a liposomal for-
mulation increases its half-life in the circulation after intravenous administration by 
avoiding rapid metabolism. Moreover, unwanted distribution in different compart-
ments of the body is avoided, so the risk of drug-related side effects is reduced. The 
versatility of liposomal drug delivery systems reflects the fact that their biophysical 
characteristics, eg, vesicle size, lamellarity, surface charge, membrane fluidity, and 
surface, can be modified by the lipid composition and/or preparation method used. 
Since naturally occurring molecules like (phospho)lipids and cholesterol are used 
as the main components, liposomes are in general classified as biocompatible.
In 1965, Bangham et al described the spontaneous formation of liquid crystals 
after dispersing lecithin in aqueous medium.2  Although the in vivo results were 
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when doubts arose about their ability to target drugs to cells 
in tissues beyond the endothelial barrier.5 Nevertheless, in 
the years since, due to discovery of steric stabilization of 
vesicles with polyethylene glycol (PEG),6,7 liposomes have 
been successfully developed as a carrier for drugs, and 
several liposomal drugs (eg, Doxil®/Caelyx® [Johnson & 
Johnson, New Brunswick, NJ, USA] and  Ambisome® 
[Gilead, Foster City, CA, USA]) have been approved and 
entered the clinic.8 
In 1978, Yatvin et al described the first temperature-
 sensitive formulation (thermosensitive liposome, TSL) that 
was able to release a hydrophilic drug when the temperature 
was increased a few degrees above  physiological temperature.9 
The original formulation based on 1,2-dipalmitoyl-sn-glyce-
ro-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-
3-phosphocholine (DSPC) 3:1 (mol/mol) has been modified 
frequently during recent decades to overcome several limi-
tations. At the beginning of the 21st century, the first TSL 
formulation developed by Needham et al entered human 
clinical trials.10 This was a breakthrough in the field, visible 
by approximately 300 citations of the original paper11 since its 
publication.  Heat-triggered drug release from liposomes can 
also be achieved by adding thermosensitive polymers to the 
formulation.12 However, in the present review, we focus on 
formulations where thermosensitivity is achieved by the bio-
physical properties of the membrane-forming  phospholipids 






































B Passive loading of gemcitabine (dFdC)
NH3
+
Figure 2 Different methods of drug loading into pre-formed liposomes.
Notes: (A) Active drug loading of weak base molecules (eg, doxorubicin) into preformed liposomes with a pH gradient. In the basic extraliposomal buffer, the drug is 
uncharged and able to transfer across the membrane bilayer. Inside, the drug is protonated due to the acidic buffer and trapped. The loading method reaches an encapsulation 
efficacy of up to 98%. (B) Passive drug loading (eg, gemcitabine) is achieved by incubating the drug and vesicles at temperatures where the membrane is in the liquid-
disordered phase state and therefore permeable for the drug. After cooling, the membrane is in the solid gel phase state, and its permeability is negligible. Because the passive 
loading is an equilibrium process depending on the ratio between intraliposomal and extraliposomal volume, the encapsulation efficacy is low and the formulation has to be 
purified from the nonencapsulated drug.
Abbreviation: dFdC, gemcitabine; DOX, doxorubicin.
Figure 1 Structure of liposomes and examples for membrane components.
Notes: (A) Schematic representation of a liposome. The vesicle is formed by a membrane bilayer of phospholipids enclosing an aqueous internal core that can be loaded 
with hydrophilic molecules (1). The vesicle surface is often shielded by a polymer coating, eg, polyethylene glycol (2). Lipophilic molecules can be incorporated into the 
membrane bilayer (3). To destabilize the membrane for facilitating drug release, surfactants (eg, lysolipids) are incorporated into the membrane (4). Surface modification with 
antibodies, antibody fragments, or ligands yields formulations for active targeting towards the desired epitope (5). Incorporation of cationic lipids like DPTAP yields vesicles 
for endosomal targeting (6). Cholesterol is incorporated to stabilize the formulations (7). (B) Examples of amphiphilic molecules forming lamellar structures. 
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Thermosensitive liposomal drug delivery systems
and highlight the influence of lipid composition on the in 
vitro and in vivo behavior of the TSL formulations currently 
under investigation. This is in contrast with previously pub-
lished reviews, which have concentrated on particular TSL 
formulations10,13,14 or image-guided drug delivery.15,16
Novel paradigm of drug targeting: 
intravascular temperature-triggered 
drug release by external targeting
Classical PEGylated long-circulating doxorubicin formula-
tions like Doxil/Caelyx have been designed to exploit the 
enhanced permeability and retention effect (Figure 3A),17 
and passively accumulate inside tumor tissue because of 
the leaky tumor vasculature. Nevertheless, passive drug 
targeting has failed to achieve increased clinical efficacy 
in humans when compared with the free drug as a result of 
several shortcomings. Accumulation depends on the specific 
structure of the tumor vasculature and might be increased 
by heating the tumor tissue.18,19 However, extravasation of 
vesicles is the rate-limiting step, and nanoparticles have to 
circulate for days to accumulate in sufficiently high concen-
trations17 because accumulation in tumor tissue competes 
with uptake in the liver and spleen, and less than 10% of 
the injected dose accumulates in the tumor.20 Doxil/Caelyx 
achieves these required long-circulating properties due to its 
high stability and ability to escape rapid recognition via the 
reticuloendothelial system. However, the bioavailability of 
doxorubicin is low.21 Seynhaeve et al demonstrated cellular 
uptake of Doxil/Caelyx via endocytosis and transfer of the 
intact vesicles to the lysosomal compartment, which mark-
edly impaired delivery of doxorubicin to the nucleus.22
Surface modification of Doxil/Caelyx with the antican-
cer monoclonal antibody 2C5 resulted in enhanced vesicle 
accumulation in mouse tumors.23 However, active targeting 
also requires extravasation of liposomes to reach deep-seated 
tumor cells and suffers from comparable shortcomings known 
for vesicles for passive targeting (Figure 3A). In recent years, 






















































Figure 3 Schematic illustration of targeting concepts with liposomes.
Notes: (A) Passive targeting of drug encapsulated in liposomes is achieved by extravasation of the vesicles into the tumor tissue due to the leaky tumor vasculature (1). 
This enhanced permeability and retention effect is the rate-limiting step in vesicle accumulation and requires highly stable liposomes with a long circulation half-life in the 
bloodstream. Even liposomes with targeting moieties attached to their surface (eg, immunoliposomes) have to exploit the enhanced permeability and retention effect to 
interact with their targets (2). An alternative approach is endothelial targeting with cationic liposomes (3). The drug delivered by stable liposomes is not fully bioavailable 
and does not reach the tumor cells in sufficient amounts (4). Even after endocytosis of the vesicles, drug delivery is limited, since the drug fails to escape from the 
endosomal compartment (5) and is subsequently degraded in the lysosome. (B) Intravascular drug release is achievable by thermosensitive liposomes. Release is externally 
steerable by changing the focus of local heating. After entering the heated tissue, the drug is released into the bloodstream (6), generating a high local drug concentration. 
The concentration gradient increases the penetration depth of the drug inside tumors (7). The heat-triggered drug release inside the target area overcomes the limitation of 
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permeability and retention effect for improving therapeutic 
efficacy has been controversially discussed.24 Another alter-
native is active targeting of tumor vessels that overexpress 
negatively charged macromolecules with cationic liposomes 
(Figure 3A).25 However, cationic liposomes are characterized 
by an increased toxicity profile and rapid clearance from the 
blood after intravenous application.25
A promising alternative, reported by Manzoor et al is 
external targeting achieved by temperature-triggered, local-
ized intravascular drug release from TSL with focused heating 
(Figure 3B).26 After reaching the heated tumor tissue, doxo-
rubicin was released directly into the bloodstream, generat-
ing a high intravascular drug concentration.26,27 This led to 
a significantly increased penetration depth of bioavailable 
doxorubicin into the tumor tissue when compared with that 
in animals treated with free doxorubicin or Doxil/Caelyx.26 
Using this approach, poorly perfused tumor areas, which are 
known to be more difficult to treat due to a hypoxia-mediated 
resistance mechanism, could also be reached. The concept of 
intravascular drug release was then extended to targeting of 
more hydrophilic drugs, such as gemcitabine.28 In contrast 
with doxorubicin, gemcitabine requires active cellular uptake 
and enzymatic intracellular activation to gemcitabine triphos-
phate. Continuous drug release should generate a consistently 
high intravascular concentration of gemcitabine during appli-
cation of hyperthermia in the target tissue, reducing the risk of 
saturation of the gemcitabine-activating enzymes. A clinical 
pharmacokinetic study demonstrated the superiority of 
extending gemcitabine exposure by a prolonged infusion 
time, resulting in increased concentrations of gemcitabine 
triphosphate inside peripheral blood mononuclear cells.29 
Additional approaches for temperature-triggered drug 
delivery have been reported. For long-circulating TSL, it seems 
reasonable to include a pre-hyperthermia treatment to open up 
the tumor vasculature for passive accumulation of TSL,18,19 
followed by a second heat trigger for interstitial drug release.30 
Such formulations might be further surface-modified for active 
targeting of the tumor vasculature31,32 or tumor cells.33,34 For 
further information about these concepts, the reader is referred 
to a recent review by Dicheva and Koning.35
Temperature-triggered drug targeting by TSL has the 
advantage of being able to externally control drug release 
spatially and temporally by steering the heating focus and 
heating power. Applicators for regional or localized heating 
of even deep-seated tumor tissue are well established in clini-
cal practice, and are used to heat tumor tissue to temperatures 
of 42°C (mild hyperthermia).36 Therefore, commonly used 
TSL are designed to release the encapsulated drug between 
39°C and 42°C. In the following sections, these formulations 
are summarized and evaluated to their suitability regarding 
the above-mentioned targeting principles.
Influence of lipid composition 
on drug release
Encapsulated hydrophilic drugs are released from TSL at the 
melting phase transition temperature (T
m
) of the lipid bilayer. 
At T
m
, the structure of the lipid bilayer changes as transfer 
from a solid gel phase (Lβ) to a liquid-crystalline phase (Lα) 
occurs (Figure 4). The membrane is more permeable to water 
and hydrophilic drugs in the liquid-crystalline phase than 
when in the gel phase.15,37 The permeability of hydrophilic 
drugs is highest at temperatures around the T
m
 because of 
the coexistence of membrane areas in both phases forming 
grain boundaries.38,39 DPPC is used as a major component in 
most TSL formulations because its T
m
 (41.4°C) is above body 
temperature.40–42 Unwanted drug leakage at body tempera-
ture can be reduced by mixing DPPC with small amounts of 
other phospholipids, such as DSPC (T
m
 =54.9°C).15,42–45 The 
composition of miscible phospholipids determines the T
m
 of 
the formulation (Figure 4B).45,46 Basic requirements for TSL 
are stable drug retention at body temperature in the presence 
of blood components and a long in vivo half-life, combined 
with a fast drug release rate around T
m




, Figure 5A) is 
commonly used in liposomes to create a steric barrier for 
inhibition of uptake by the reticuloendothelial system and 
increased blood circulation time,47–49 but also potentially 
affects vesicle stability (Figure 5B).50 In addition to phos-
pholipid composition, the manifestation of heat-triggered 
drug release depends to some degree on the drug molecule 
encapsulated (Figure 4C),28,51,52 vesicle size,51 and the pres-
ence of serum components.45,52 
In vitro and in vivo behavior 
of selected formulations
Until now distinct liposomal formulations have been 




In 1995, Gaber et al reported the effect of cholesterol and 
PEG-phosphatidylethanolamine with regard to stabilizing 
TSL formulations in vitro.45 Incorporation of 30 mol% 
cholesterol into TSL formulations eliminated T
m
 by chang-
ing the phase state of the membrane to a liquid-ordered 
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Thermosensitive liposomal drug delivery systems
DPPE-PEG 50:25:15:3 (mol/mol) released 60% of their 
doxorubicin content during 30 minutes of incubation at 42°C 
in human plasma.45 In vivo fluorescence video microscopy 
in rats revealed liposome extravasation.53 The doxorubicin 
content in the interstitial space was negligible at 34°C, but 
increased by 38-fold when the tumor was heated to 42°C 
for one hour.53 A traditional temperature-sensitive liposome 
(TTSL) formulation with coencapsulated doxorubicin and a 
gadolinium-based contrast agent for MRI-guided delivery 
of doxorubicin is currently under investigation.54–57 The 
TTSL formulation has been used in these studies because 
of its higher stability when compared with lysolipid-




The breakthrough in development of clinically usable 
TSL formulations was the incorporation of lysolipids into 
the membrane bilayer, as described by Needham et al in 
2000.11 The LTSL formulation was originally composed of 
DPPC/lyso-PC/DSPE-PEG
2000
 90:10:4 (mol/mol; Table 1), 
but was modified slightly in recent years.10 The surfactant, 
lyso-PC (Figure 5A), mediates drug release around T
m
 by 
formation of lysolipid-stabilized membrane pores.10,50,58 The 
release rate of doxorubicin from LTSL at 41.3°C was 80% in 
20 seconds.14 In comparison, TTSL released only 40% of its 
doxorubicin content in 30 minutes on heating to 42°C.11,59
Complete regression of tumors was achieved in a preclini-
cal xenograft mouse model using doxorubicin encapsulated in 
LTSL.60 In an orthotopic murine mammary model, reduction 
of blood flow and microvascular density occurred after local 
application of hyperthermia.61 Four xenograft models have 
been studied, and show that LTSL had improved efficacy in 
comparison with TTSL.62 In 2006, Hauck et al published a 
Phase I study of LTSL performed in dogs with spontaneously 
grown solid tumors.63 The tumor response achieved supported 
further evaluation of this formulation, but the maximum 
tolerated dose of 0.93 mg/kg was slightly lower than the 
published dose for free doxorubicin in dogs.63 The LTSL 
A
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Figure 4 Factors affecting drug release from thermosensitive liposomes.
Notes: (A) The encapsulated drug is released by passive transfer driven by a concentration gradient (1). At body temperature, the phospholipids are in the solid gel (Lβ) phase 
state characterized by low permeability to hydrophilic compounds (2). By increasing the temperature above the phase transition temperature (Tm), the phospholipids are in a 
liquid-crystalline (Lα) phase state with higher permeability to hydrophilic compounds, because of the higher disorder and movement in the phospholipid packing (3). Around 
Tm, permeability is the highest because of coexistence of membrane areas in both phases (4). Permeability is further mediated by disturbances in lipid packing induced by lipid 
incorporation (5), lipid loss (7), and interaction with blood components (8–10). As a specific mechanism of ultrafast drug release from lysolipid-containing TSL, the formation 
of membrane pores (6) by lysolipids around Tm was shown. (B) Tm of DPPC/DSPC/DPPG2 50:20:30 (mol/mol) (DPPG2-TSL) measured by dynamic scanning calorimetry. 
(C) Temperature-dependent release of hydrophilic compounds from DPPG2-TSL measured in fetal calf serum. 
Abbreviations: CF, carboxyfluorescein; dFdC, gemcitabine; DOX, doxorubicin; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DSPC, 1,2-distearoyl-sn-glycero-3-
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formulation with encapsulated doxorubicin (Thermodox®) 
was licensed to Celsion Corporation (Columbia, MD, USA) 
and is currently under clinical investigation.10,64 Woo et al 
encapsulated cisplatin into LTSL, but until now only in 
vitro tests have been published.65 Clinical development of 
the LTSL formulation was recently reviewed in detail, so 
interested readers are referred to this publication.10
LTSL was the first TSL formulation suitable for use in 
the intravascular drug release approach. This formulation is 
characterized by ultrafast drug release upon heating, although 
incorporation of surfactants in the formulation decreases 
vesicle stability around T
m
.50 Moreover, approximately 70% 
of lysolipid was found to dissociate from the formulation 
within one hour post injection.66 
DPPG2-thermosensitive liposome
In 2004, a new liposomal formulation (DPPG
2
-TSL) 
composed of the phospholipids DPPC, DSPC, and 
Amphiphilic molecules forming micellar structures No surfactants











































Figure 5 Micellar-forming amphiphilic molecules as membrane component in liposomes.
Notes: (A) Example of micellar-forming amphiphilic molecules (surfactants) used in liposomal formulations. DSPE-PEG2000 is used to increase the circulation half-life of 
liposomes, and lyso-PC, Brij78, and HePC can be used in thermosensitive formulations to facilitate drug release. (B) Surfactants are incorporated into the membrane bilayers 
at a low molecular content, but induce formation of usually unwanted structures (eg, membrane pores, dissolution of liposomes) at high concentrations.
Abbreviations: DSPE-PEG2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(PEG)-2000; lyso-PC, acyl-sn-glycero-3-phosphocholine; Brij78, polyoxyethylene 
(20) stearyl ether; HePC, hexadecylphosphocholine.


































DPPG2-TSL DPPC/DSPC/ DPPG2 
50:20:30 (mol/mol) 







Stealth TSL DPPC/DSPC/ DSPE-
PEG2000
80:15:5 (mol/mol)
200746 43.0°C72 Doxorubicin27,72 – Passive targeting 
before heat-triggered, 
interstitial drug release
HaT DPPC/Brij78 96:4  
(mol/mol)
201173 41.0°C74 Doxorubicin73 
Gemcitabine75
Oxaliplatin75





201377 – Doxorubicin77 – Intravascular drug 
release
Abbreviations: Brij78, polyoxyethylene (20) stearyl ether; DPPE-PEG, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(PEG); DPPG2, 1,2-dipalmitoyl-sn-
glycero-3-phosphodiglycerol; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPE-PEG2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(PEG)-2000; 
ELP, fatty acid conjugated elastin-like polypeptide; Gd, gadolinium; HaT, liposome hyperthermia-activated cytotoxic formulation; DPPC, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine; HSPC, hydrogenated soy phosphatidylcholine; LTSL, lysolipid-containing low-temperature sensitive liposomes; Mn, manganese; MRI, magnetic resonance 
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was reported by Lindner et al.67 DPPG
2
 is a synthetic phos-
pholipid with a molecular weight close to that of natural 
occurring 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol, 
because only one additional glycerol molecule is bound via 
an ether bond to the head group.67 The molecular class of 
oligoglycerols (Figure 1B, DPPG
n
) was developed to increase 
the circulation half-life of vesicles in the same way as for 
PEGylated lipids. Lasic et al postulated that highly hydrated 
groups like PEG on the liposomal surface are capable of 
sterically inhibiting electrostatic and hydrophobic interac-
tions with blood components.68 Incorporation of DPPG
2
 led 
to a prolonged circulation time in non-thermosensitive69 
and thermosensitive28,67 formulations. The plasma half-life 
of carboxyfluorescein encapsulated into DPPG
2
-TSL was 
reported to be 9.6 hours in hamsters and 5 hours in rats.67 
Because of the significantly smaller head group modification 
of the phospholipid compared to DSPE-PEG
2000
 (74 Da versus 
approximately 2,000 Da), DPPG
n
 forms lamellar structures 
and could be incorporated into TSL formulations with up 
to 70 mol%.67 Incorporation of DSPE-PEG
2000
 instead is 
limited to concentrations below 10% mol, since it acts like 





-TSL is around 42°C, with a narrow 
transition range (Figure 4B). 
In contrast with the LTSL formulation, incorporation 
of surfactants into DPPG
2
-TSL was avoided. However, 
the release rates of carboxyfluorescein and doxorubicin 
from DPPG
2
-TSL were as fast as measured with the LTSL 
formulation,46 but drug release from the DPPG
2
-TSL formula-
tion started at approximately one degree higher temperature.46 
DPPG
2
-TSL showed improved in vitro stability in complete 
serum when compared with LTSL.52 The presence of serum 
components at 37°C stabilized the formulation over time, 
whereas the opposite was found for LTSL. Interestingly, the 
lipid composition of a TSL formulation markedly influenced 
the effect of serum components on vesicle stability. DPPC/
DSPC/DSPE-PEG
2000 
80:15:5 (mol/mol) (Stealth TSL) and 
LTSL were more susceptible towards destabilizing effects 
by cholesterol-containing vesicles,52 whereas the presence 
of immunoglobulin type G stronger affected the stability of 
DPPG
2
-TSL.52 Moreover, the stability of DPPG
2
-TSL was 
less affected by size changes in the range of 100–150 nm 
compared to surfactant containing LTSL.51
Incorporation of 10% mol hexadecylphosphocholine 
(HePC; Figure 5A) into the membrane of DPPG
2
-TSL further 
increased the release rate of the encapsulated drug, similar 
to lyso-PC.71 HePC is structurally related to lyso-PC, but has 
better chemical and metabolic stability, and is approved as a 
lipophilic drug for the treatment of skin metastasis in breast 
cancer and for leishmaniasis. The in vitro cytotoxicity of HePC 
in DPPG
2
-TSL was heat-inducible and stronger than that 
induced by micellar HePC, which did not respond to heat.71
Limmer et al passively loaded gemcitabine into DPPG
2
-
TSL,28 and their pharmacokinetic studies in rats using gemcit-
abine 6 mg/kg body weight showed an initial plasma half-life of 
0.53 hours for gemcitabine encapsulated in DPPG
2
-TSL, with 
a size of 109 nm. The plasma half-life was increased to 2.59 
hours when the vesicle size was increased to 129 nm. In a thera-
peutic study, significant delay of tumor growth was found for 
heat-triggered gemcitabine from DPPG
2
-TSL when compared 






-TSL is currently the only TSL formulation that 
fulfills all the criteria for heat-triggered intravascular drug 
release. Drug release upon activation from this formulation 
is comparable fast as observed with LTSL formulation. 
Moreover, the absence of surfactants yields a long-circulating 
formulation, with high plasma levels after intraveneous 
application for the duration of a typical hyperthermia treat-
ment in the clinic.
Stealth TSL
A sterically stabilized TSL formulation (Stealth TSL; 
Table 1) was developed from the original Yatvin formula-
tion by adding DSPE-PEG
2000
 for improved stability and 
a better in vivo half-life when compared with the LTSL 
formulation,46,72 and enabled passive accumulation of TSL 
in tumor tissue.19 Li et al compared Stealth TSL and LTSL, 
and found that the former had superior in vitro stability at 
37°C in serum.27 The maximum release of doxorubicin from 
Stealth TSL was at 42°C.27 In comparison with LTSL, release 
of doxorubicin from Stealth TSL starts at higher temperatures 
(39°C versus 37°C).27 Because of the absence of lyso-PC in 
Stealth TSL, the rate of release of doxorubicin at 42°C was 
slower (75%, one minute) when compared with LTSL (99%, 
one minute).27 In a BFS-1 mouse model, Stealth TSL showed 
improved tumor growth control over LTSL when combined 
with mild hyperthermia.27 Recently, Li et al published a two-
step treatment approach.30 After prehyperthermia treatment 
to open up the tumor vasculature,18,19 Stealth TSL passively 
accumulated in the tumor tissue, and a subsequent second 
hyperthermia treatment allowed interstitial drug release 
for precise intratumoral drug delivery.30 Nevertheless, in 
tumor growth delay studies, this treatment was less effective 
than the intravascular temperature-triggered drug release 
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Another TSL formulation with encapsulated doxorubicin 
currently under investigation is the hyperthermia-activated 
cytotoxic (HaT) liposome formulation described by Tagami 
et al (Table 1).73 HaT is composed of DPPC and the non-
ionic surfactant, polyoxyethylene (20) stearyl ether (Brij78; 
Figure 5A). Brij78 consists of a PEGylated acyl chain, so it 
was hypothesized that Brij78 could replace the function of 
lyso-PC and DSPE-PEG
2000
 in the LTSL formulation.73,74 The 
HaT formulation showed 100% doxorubicin release within 
3 minutes at a temperature of 40°C–42°C in buffer.74 In 
comparison with LTSL, HaT showed enhanced drug release 
rates at 40°C, with similar blood pharmacokinetics.73 For both 
formulations, a blood circulation half-life of approximately 
0.5 hours was observed after injection.73 A single intravenous 
treatment with HaT at a doxorubicin dose of 3 mg/kg body 
weight in combination with local hyperthermia showed 
enhanced tumor regression when compared with LTSL.73
Gemcitabine and oxaliplatin have also been encapsulated 
into the HaT formulation.75 In a pharmacokinetic study in 
mice, 40% of the injected dose was detectable 2 hours after 
intravenous administration of gemcitabine encapsulated in 
HaT.75 For oxaliplatin, a three-fold reduction in clearance was 
observed in comparison with the free drug.75 HaT showed a 
25-fold improvement in delivery of gemcitabine to the heated 
tumor relative to free gemcitabine.75 Unfortunately, superi-
ority of external targeting was not shown in the therapeutic 
study, because there was no appropriate control group (ie, 
HaT without hyperthermia).
In 2012, Tagami et al reported an improved method for 
active loading of doxorubicin into the HaT formulation based 
on a copper(II) gradient (HaT-II).76 HaT-II showed improved 
in vitro stability at 37°C, together with a faster drug release 
rate at 41°C in the presence of serum when compared with 
LTSL.76 In comparison with LTSL, HaT-II showed a 2.5-
fold longer blood circulation time in mice and a 2.0-fold 
increase in drug delivery to the heated tumor.76 This resulted 
in improved antitumor efficacy.76
STL formulation
In 2013, Park et al reported another stabilized formulation 
composed of DPPC, DSPE-PEG
2000
, cholesterol, and fatty 
acid-conjugated elastin-like polypeptide 55:2:15:0.4125 
(mol/mol) (STL) with encapsulated doxorubicin (Table 1).77 
Pharmacokinetic studies in mice showed plasma half-lives 
of 2.03 hours and 0.92 hours for doxorubicin encapsulated 
in STL and LTSL,77 respectively. In combination with high 
intensity focused ultrasound, STL achieved significantly 
better tumor growth delay 7 days after injection when com-
pared with LTSL.77
Thermosensitive liposomes 
for MRI-guided drug delivery
MRI is the method of choice for image-guided drug delivery 
with TSL. Its abilities with regard to morphological and 
functional tumor characterization without exposure to ion-
izing radiation are well known, and it is a standard method 
in clinical use. Further, MRI thermometry is established for 
the control of thermotherapies, such as radiofrequency hyper-
thermia and high intensity focused ultrasound. Dedicated 
hybrid systems have already been introduced into clinical 
applications.15,78,79 Localized drug release from TSL has 
been demonstrated in rodents,55,80 and nonrodents,81–83 using 
MRI for the control of hyperthermia. Beyond controlling the 
volume of heating, encapsulation of MRI contrast agents in 
TSL formulations allows additional characterization of the 
drug delivery only accessible in humans when using MRI. 
Signal mechanism
Paramagnetic gadolinium chelates54,82,84–86 and manganese 
ions87–90 are typical MRI-active contrast agents for encapsula-
tion in TSL formulations (Table 1). The nuclear magnetic reso-
nance of water protons is the primary origin of MRI signal and 
not the contrast agent itself. MRI contrast agents are only visu-
alized by their ability to accelerate the water proton relaxation 
in the vicinity of the contrast agent molecules. This indirect 
signal forming process is only effective if the contrast agent 
molecule is allowed to interact with a large number of water 
protons. For visualization of temperature-induced release, the 
contrast agent has to be encapsulated inside the TSL.91–93 Below 
the T
m
, the contrast agent interacts mainly with the water pres-
ent inside the TSL, because water exchange with the exterior 
of the TSL is limited. As a result, the visibility of the contrast 
agent is reduced when compared with free contrast agents. 
When approaching the T
m
, the increase in water exchange 
results in a signal increase in T
1
-weighted images.84 Around 
the T
m
, the contrast agent is released and the signal change is 
maximal and comparable with the signal change achieved with 
free contrast agent.84,86,91,92 This makes it possible to strongly 
change an MRI signal by altering temperature.92
The maximum achievable signal change depends on the 
type of contrast agent,86 lipid composition,86,91 vesicle size,51,91 
and concentration of the encapsulated contrast agent.86,91 
The heating method might also play a role, eg, focused 
ultrasound adds a mechanical release component to the 
signal mechanism.15 The signal mechanism described in 
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induced change of the longitudinal (T
1
) relaxation time of 
the water protons. But signal formation in MRI is complex, 
often showing a weighted signal depending not only on the 
T
1
 relaxation time shortening effect but also on the type of 
pulse sequence, choice of sequence parameters, and effects 
related to T
2
 relaxation. Quantification strategies in MRI 
thus try to determine a single parameter, such as the T
1
 
relaxation time, with the aim of being independent of vari-
ables such as system settings of an individual measurement 
or inhomogeneity of the receiver coil. T
1
 relaxation remains 
the parameter of choice because it is directly related to the 
membrane dynamics. 
Applications
TSL can be applied with an encapsulated contrast agent to 
distinguish heated from unheated tissue85,94 or to quantify 
absolute temperatures complementing traditional MRI 
thermometry methods,95,96 thus serving as a tool for quality 
assurance in thermotherapy in patients. 
It has been demonstrated that potentially quantitative 
estimation of drug release based on T
1
 relaxation time 
changes is possible if the contrast agent and drug are both 
encapsulated in a TSL formulation,55,87–89,97 thus allowing 
“drug dose painting”89 or “chemodosimetry”.88 Because the 
drug itself is not observed by MRI, a correlation between 
the contrast agent and drug release had to be established. 
For that purpose, LTSL were actively loaded with doxo-
rubicin using a manganese(II) gradient.87 Doxorubicin and 
manganese(II) form a stable complex,98 with the paramag-
netic manganese(II) serving as an MRI contrast agent. Thus 
the release kinetics are the same for the contrast agent and 
the drug, allowing for correlation between change in T
1
 relax-
ation time (determined by MRI) and amount of doxorubicin 
(determined by high-performance liquid chromatography).88 
Using this strategy, it was possible to show that release of 
doxorubicin was heterogeneously distributed in the tumor 
model, and that LTSL administered during hyperthermia 
had the greatest antitumor effect when compared with other 
administration strategies.
The major drawback of the above approach is the toxicity 
related to manganese(II). 
To overcome this, other researchers are using clinically 
approved gadolinium-based contrast agents. Hossann et al 
investigated six of these contrast agents for encapsulation 
in DPPG
2
-TSL, and considered a nonionic contrast agent 
with a low contribution to osmolality to be optimal.86 Two 
strategies of encapsulation are possible using gadolinium-
based contrast agents, but the release kinetics and signal 
mechanisms for both the contrast agent and drug have to 
be considered. One strategy is to combine two subsets of 
TSL, with one encapsulating only the contrast agent and a 
second encapsulating only the drug.99 This strategy allows a 
higher amount of contrast agent and drug to be encapsulated 
whilst avoiding osmotic effects.86 The second strategy is 
to coencapsulate both drug and contrast agent in the same 
TSL,54–57,82,83,97 which limits the amount of both components 
in each TSL. Nevertheless, for both strategies, it has to be 
ensured that the temperature-dependent drug release rate and 
MRI signal change are correlated.82
An important risk associated with clinical application of 
a gadolinium-based contrast agent is nephrogenic systemic 
fibrosis, a rare side effect in patients. The pathophysiologi-
cal mechanism involves a reduced glomerular filtration rate 
and a long retention time combined with transmetallation of 
gadolinium(III). Hijnen et al addressed this concern in a rat 
model, but could not detect dissociation of gadolinium-DTPA 
in high intensity focused ultrasound ablation therapy.100 De 
Smet et al investigated the blood kinetics and biodistribu-





O) in Fisher rats,57 and found 
significant clearance with #0.3% of the injected dose in all 
analyzed organs one month after injection. Nevertheless, 
before application in humans, further investigation of the 
risks associated with this strategy seems necessary. 
Conclusion
TSL are a promising tool for external targeting of drugs to 
solid tumors in combination with local hyperthermia or high 
intensity focused ultrasound. Several formulations have been 
developed, with one currently under clinical investigation. 
In vivo results show strong evidence that external targeting 
is superior over passive targeting of highly stable long-
circulating drug formulations. Moreover, MRI-guided drug 
delivery adds the possibilities of online monitoring of heating 
focus, calculating locally released drug concentrations, and 
externally controlling drug release by steering the heating 
focus and power. The combination of external targeting 
with TSL and MRI-guided drug delivery will be the unique 
characteristic of this nanotechnology approach in medicine.
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